Many doctors, including dermatologists, would rather not address patients’ feelings about psoriasis. It’s part of how dermatologists protect themselves from bearing the burdens of patients’ woes, according to Richard Fried, M.D., Ph.D., a dermatologist and clinical psychologist in Yardley, Pennsylvania.
Treatments for Plaque Psoriasis
Psoriasis in nonwhite patient populations is not well described, according to Andrew F. Alexis, M.D., M.P.H., director of the Skin of Color Center, at St. Luke’s Roosevelt Hospital, Mount Sinai Health System, New York.
Common gastrointestinal side effects to methotrexate may include anticipatory, associative and behavioral symptoms, aside from post-treatment nausea and vomiting, according to a new report.
Recent head-to-head clinical trial results with secukinumab (Novartis) and etanercept (Enbrel, Amgen) show a significant superiority of secukinumab in the treatment and management of patients with moderate-to-severe plaque psoriasis, perhaps heralding a new standard of care for this patient population.
The human interleukin-12 and interleukin-23 (IL-12/IL-23) inhibitor ustekinumab (Stelara, Janssen) is effective and is well tolerated in patients who have active psoriatic arthritis.
Up to 30 percent of patients with psoriasis do not seek medical care for their skin condition, patient surveys show.
People who live with psoriasis have a higher risk of death from cardiovascular disease.
The rate of adverse events in patients using adalimumab remains low over time, with infections indicated as the most common adverse event, according to a study.